Sarepta therapeutics reports preliminary* fourth quarter and full-year 2024 net product revenue

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of december 31, 2024, as part of its presentation today at the 43rd annual j.p. morgan healthcare conference in san francisco, calif. financial update* (preliminary and unaudited): total net product revenue of $638.2 million for the fourth quarter and $1.79 bi.
SRPT Ratings Summary
SRPT Quant Ranking